New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells - PubMed (original) (raw)
. 2009 Sep;100(9):1719-27.
doi: 10.1111/j.1349-7006.2009.01220.x. Epub 2009 May 18.
Brian Hutzen, Sarah Ball, Elizabeth Foust, Matthew Sobo, Stephanie Deangelis, Bulbul Pandit, Lauren Friedman, Chenglong Li, Pui-Kai Li, James Fuchs, Jiayuh Lin
Affiliations
- PMID: 19558577
- PMCID: PMC11158315
- DOI: 10.1111/j.1349-7006.2009.01220.x
New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells
Li Lin et al. Cancer Sci. 2009 Sep.
Abstract
Curcumin, the active component of turmeric, has been shown to protect against carcinogenesis and prevent tumor development in cancer. To enhance its potency, we tested the efficacy of synthetic curcumin analogues, known as FLLL11 and FLLL12, in cancer cells. We examined the impact of FLLL11 and FLLL12 on cell viability in eight different breast and prostate cancer cell lines. FLLL11 and FLLL12 (IC(50) values 0.3-5.7 and 0.3-3.8 micromol/L, respectively) were substantially more potent than curcumin (IC(50) values between 14.4-50 micromol/L). FLLL11 and FLLL12 were also found to inhibit AKT phosphorylation and downregulate the expression of HER2/neu. In addition, we demonstrate for the first time that FLLL11 and FLLL12 inhibit phosphorylation of signal transducer and activator of transcription (STAT) 3, an oncogene frequently found to be persistently active in many cancer types. The inhibition of STAT3 signaling was confirmed by the inhibition of STAT3 DNA binding and STAT3 transcriptional activity. Furthermore, FLLL11 and FLLL12 were more effective than curcumin in inhibiting cell migration and colony formation in soft agar as well as inducing apoptosis in cancer cells. These results indicate that FLLL11 and FLLL12 exhibit more potent activities than curcumin on the inhibition of STAT3, AKT, and HER-2/neu, as well as inhibit cancer cell growth and migration, and may thus have translational potential as chemopreventive or therapeutic agents for breast and prostate cancers.
Figures
Figure 1
(a) The chemical structures of curcumin, FLLL11, and FLLL12. (b) The general synthesis scheme for FLLL11 and FLLL12.
Figure 2
The inhibitory effects of AKT phosphorylation and HER‐2/neu protein expression by FLLL11, FLLL12, and curcumin in (a) BT‐474, (b) SK‐BR‐3, (c) MDA‐MB‐453, and (d) PC‐3 human cancer cell lines. Cancer cells were treated with 5–10 µmol/L FLLL11 and FLLL12, or 5–10 µmol/L curcumin for 24 h. Membranes were blotted with HER‐2/neu, phospho‐specific AKT (S473), cleaved poly (ADP‐ribose) polymerase (PARP), cleaved caspase‐3, and GAPDH antibodies.
Figure 3
FLLL11 and FLLL12 inhibit STAT 3 phosphorylation in (a) MDA‐MB‐231, (b) SK‐BR‐3, and (c) DU145 breast and prostate cancer cells. Cells were treated for 24 h. Membranes were blotted with phospho‐specific STAT3, phospho‐independent STAT3, phospho‐specific ERK1/2, cleaved poly (ADP‐ribose) polymerase (PARP), cleaved caspase‐3, and GAPDH antibodies. (d) FLLL11 and FLLL12 (10 µmol/L) induce cleaved PARP and cleaved caspase‐3 in breast cancer cells but not in human mammary epithelial cells (HMEC) and WI‐38 normal human lung fibroblasts. The inhibitory effects of FLLL11 and FLLL12 on STAT3 DNA binding activity in (e) MDA‐MB‐231 (f), SK‐BR‐3, and (g) DU145 cancer cells. The nuclear extracts were analyzed for STAT3 DNA binding activity using STAT3‐specific TransFactor kit. Statistical significance (P < 0.01) relative to the DMSO vehicle control is designated by an asterisk. (h) The inhibitory effect of FLLL11 and FLLL12 on STAT3‐dependent transcriptional activity was analyzed in MDA‐MB‐231 breast cancer cells that stably integrate the STAT3‐dependent luciferase reporter construct. The data were subsequently normalized and presented here as percentages of the DMSO vehicle control. Asterisks denote statistically significant (P < 0.01) decreases in luciferase activity.
Figure 3
FLLL11 and FLLL12 inhibit STAT 3 phosphorylation in (a) MDA‐MB‐231, (b) SK‐BR‐3, and (c) DU145 breast and prostate cancer cells. Cells were treated for 24 h. Membranes were blotted with phospho‐specific STAT3, phospho‐independent STAT3, phospho‐specific ERK1/2, cleaved poly (ADP‐ribose) polymerase (PARP), cleaved caspase‐3, and GAPDH antibodies. (d) FLLL11 and FLLL12 (10 µmol/L) induce cleaved PARP and cleaved caspase‐3 in breast cancer cells but not in human mammary epithelial cells (HMEC) and WI‐38 normal human lung fibroblasts. The inhibitory effects of FLLL11 and FLLL12 on STAT3 DNA binding activity in (e) MDA‐MB‐231 (f), SK‐BR‐3, and (g) DU145 cancer cells. The nuclear extracts were analyzed for STAT3 DNA binding activity using STAT3‐specific TransFactor kit. Statistical significance (P < 0.01) relative to the DMSO vehicle control is designated by an asterisk. (h) The inhibitory effect of FLLL11 and FLLL12 on STAT3‐dependent transcriptional activity was analyzed in MDA‐MB‐231 breast cancer cells that stably integrate the STAT3‐dependent luciferase reporter construct. The data were subsequently normalized and presented here as percentages of the DMSO vehicle control. Asterisks denote statistically significant (P < 0.01) decreases in luciferase activity.
Figure 4
The ability of MDA‐MB‐231 breast cancer cells to form colonies in soft agar is decreased following treatment with 5 µmol/L curcumin or 1–5 µmol/L FLLL11 and FLLL12 in (a) MDA‐MB‐231 and (b) SK‐BR‐3 breast cancer cells. (c) Migration of MDA‐MB‐231 into a scratch wound is impeded after 4 h of treatment with curcumin, FLLL11, or FLLL12. (d) MTT assays of MDA‐MB‐231 cells reveal that the dosages of these agents used in the migration assay have minimal impact on viability over 4 h of drug treatment and an additional 20 h without treatment.
Figure 5
The inhibitory effects of cell viability by FLLL11 and FLLL12 in combination with doxorubicin in the MDA‐MB‐231 human breast cancer cell line. MDA‐MB‐231 breast cancer cells were treated with (a) FLLL11, (b) FLLL12, and doxorubicin for 72 h. The cell viability was determined by MTT assay. The untreated cells were set at 100% and the viability of doxorubicin‐, FLLL11‐, and FLLL12‐treated cells was determined relative to the untreated cells. Asterisks represent synergism (a combinational index less than 1).
Similar articles
- Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells.
Friedman L, Lin L, Ball S, Bekaii-Saab T, Fuchs J, Li PK, Li C, Lin J. Friedman L, et al. Anticancer Drugs. 2009 Jul;20(6):444-9. doi: 10.1097/CAD.0b013e32832afc04. Anticancer Drugs. 2009. PMID: 19384191 Free PMC article. - The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via STAT3 inhibition.
Wang X, Zhang Y, Zhang X, Tian W, Feng W, Chen T. Wang X, et al. Int J Oncol. 2012 Apr;40(4):1189-95. doi: 10.3892/ijo.2011.1298. Epub 2011 Dec 14. Int J Oncol. 2012. PMID: 22179587 Free PMC article. - Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li PK, Li C, Fuchs J, Lin J. Lin L, et al. Cancer Res. 2010 Mar 15;70(6):2445-54. doi: 10.1158/0008-5472.CAN-09-2468. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215512 Free PMC article. - Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas.
Hutzen B, Friedman L, Sobo M, Lin L, Cen L, De Angelis S, Yamakoshi H, Shibata H, Iwabuchi Y, Lin J. Hutzen B, et al. Int J Oncol. 2009 Oct;35(4):867-72. doi: 10.3892/ijo_00000401. Int J Oncol. 2009. PMID: 19724924 - Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review.
Golmohammadi M, Zamanian MY, Al-Ani AM, Jabbar TL, Kareem AK, Aghaei ZH, Tahernia H, Hjazi A, Jissir SA, Hakimizadeh E. Golmohammadi M, et al. Animal Model Exp Med. 2024 Sep 2. doi: 10.1002/ame2.12491. Online ahead of print. Animal Model Exp Med. 2024. PMID: 39219410 Review.
Cited by
- Effects of curcumin and ursolic acid in prostate cancer: A systematic review.
Besasie BD, Saha A, DiGiovanni J, Liss MA. Besasie BD, et al. Urologia. 2024 Feb;91(1):90-106. doi: 10.1177/03915603231202304. Epub 2023 Sep 30. Urologia. 2024. PMID: 37776274 Free PMC article. Review. - Curcumin and its Derivatives Targeting Multiple Signaling Pathways to Elicit Anticancer Activity: A Comprehensive Perspective.
Fatima F, Chourasiya NK, Mishra M, Kori S, Pathak S, Das R, Kashaw V, Iyer AK, Kashaw SK. Fatima F, et al. Curr Med Chem. 2024;31(24):3668-3714. doi: 10.2174/0929867330666230522144312. Curr Med Chem. 2024. PMID: 37221681 Review. - Synthesis of Novel Bis-imino and Bis-amino Curcuminoids for Evaluation of Their Anticancer and Antibacterial Activity.
Mathur P, Mori M, Vyas H, Mor K, Jagtap J, Vadher S, Vyas K, Devkar R, Desai A. Mathur P, et al. ACS Omega. 2022 Dec 2;7(49):45545-45555. doi: 10.1021/acsomega.2c06177. eCollection 2022 Dec 13. ACS Omega. 2022. PMID: 36530297 Free PMC article. - Ethanolic extract of Origanum syriacum L. leaves exhibits potent anti-breast cancer potential and robust antioxidant properties.
Mesmar J, Abdallah R, Hamade K, Baydoun S, Al-Thani N, Shaito A, Maresca M, Badran A, Baydoun E. Mesmar J, et al. Front Pharmacol. 2022 Oct 10;13:994025. doi: 10.3389/fphar.2022.994025. eCollection 2022. Front Pharmacol. 2022. PMID: 36299882 Free PMC article. - Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL‑6/STAT3 signaling pathway.
Shi W, Men L, Pi X, Jiang T, Peng D, Huo S, Luo P, Wang M, Guo J, Jiang Y, Peng L, Lin L, Li S, Lv J. Shi W, et al. Int J Oncol. 2021 Dec;59(6):99. doi: 10.3892/ijo.2021.5279. Epub 2021 Nov 2. Int J Oncol. 2021. PMID: 34726248 Free PMC article.
References
- Ni Z, Lou W, Leman E, Gao A. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 2000; 60: 1225–8. - PubMed
- Davies M, Koul D, Dhesi H et al . Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999; 59: 2551–6. - PubMed
- Mora LB, Buettner R, Seigne J et al . Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659–66. - PubMed
- Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004; 3: 11–20. - PubMed
- Slamon D, Godolphin W, Jones L et al . Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous